(
A) Schematic of short pitch crosslinking assay using dual cysteine engineered Arp2/3 complex and bis-maleimidoethane (BMOE). (
B) Quantification of western blots of crosslinking reactions in which BMOE was added to a dual cysteine engineered Arp2/3 complex (1 μM) and 200 μM ATP in the presence or absence of 10–20 μM Wsp1-VCA, 45–50 μM Dip1, and 15 μM LatA-actin, as indicated. Reactions were incubated for 1 min at room temperature. Error bars show standard deviation. p-values: **<0.1, ***<0.001. (
C) Western blot of GST-Wsp1-VCA pulldown assays. Binding reactions contained 235 μM GST-Wsp1-VCA on glutathione sepharose beads, 50 μM Dip1, 9.1 μM SpArp2/3(Arp3ΔC) complex, and 25 μM LatB-actin (from rabbit skeletal muscle) as indicated. The SpArp2/3(Arp3ΔC) mutant complex was used for these assays because it binds more tightly to Wsp1-VCA (
Rodnick-Smith et al., 2016a). (
D) Quantification of the fraction of Dip1 pelleted in reactions described in C. Error bars show the mean with standard deviation.